RayKnowChina Research Map
Shortlist

SuzhouSoochow University

Second Affiliated Hospital of Soochow University

苏州大学附属第二医院

Listed for 17 of the 61 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Second Affiliated Hospital of Soochow University

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 61 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌5 papers led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌4 papers led
  3. Stomach cancer胃癌32 papers led
  4. Lung cancer肺癌64 papers led1 open trial led
  5. Pancreatic cancer胰腺癌11 papers led
  6. Breast cancer乳腺癌27 papers led1 open trial led
  7. Glioma胶质瘤44 papers led
  8. Osteosarcoma骨肉瘤13 papers led
  9. Gastrointestinal stromal tumour胃肠道间质瘤1 paper led
  10. Ewing sarcoma尤文肉瘤2 papers led
  11. Multiple myeloma多发性骨髓瘤2 papers led
  12. Lymphoma淋巴瘤10 papers led3 open trials led
  13. Fabry disease法布雷病0 papers led
  14. Duchenne muscular dystrophy杜氏肌营养不良0 papers led
  15. Behçet disease白塞病1 paper led
  16. IgA nephropathyIgA 肾病1 paper led
  17. Primary biliary cholangitis原发性胆汁性胆管炎0 papers led

Not listed for: Hepatocellular carcinoma, Hepatoblastoma, Retinoblastoma, Chordoma, Neuroblastoma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Coronary heart disease, Congenital heart disease, Scoliosis, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Pompe disease, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 5 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 2220242025: 112025

2 hospitals in Suzhou for nasopharyngeal carcinoma183 hospitals in China for nasopharyngeal carcinoma

No open trial on nasopharyngeal carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesRadiotherapy techniqueInduction / concurrent chemotherapyImaging & AI
Departments in papersRadiation oncologyGastroenterology / hepatologyENT / head & neck surgeryNeurosurgery

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 4 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 1120242025: 112025

4 hospitals in Suzhou for oesophageal squamous cell carcinoma192 hospitals in China for oesophageal squamous cell carcinoma

No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesImaging & AIMolecular markers & genomicsSurgery
Departments in papersMedical oncologyRadiation oncology

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 32 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.3%.

Papers led
32
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 5520212022: 4420222023: 101020232024: 8820242025: 552025

4 hospitals in Suzhou for stomach cancer211 hospitals in China for stomach cancer

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer
    Phase
    N/A
    Started
    2026-06
    Posted
    Registry
    NCT07552402

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Chengdu, Dalian, Fuzhou, Hangzhou, Nanning, Shanghai, Shijiazhuang, Suzhou, Wuhan, Yinchuan

  2. Recruiting
    Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
    Phase
    Phase 3
    Started
    2025-02
    Posted
    Registry
    NCT06731478

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changzhou, Fuzhou, Hangzhou, Harbin, Hefei, Jinan, Lanzhou, Linyi, Shanghai, Shenyang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yinchuan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesSurgeryPeritoneal spread & advanced diseaseNutrition & recovery
Departments in papersSurgery (general/hepatobiliary/pancreatic)Medical oncologyRadiation oncologyPathology / laboratory medicine

Over half of these papers are lab or animal studies.

Papers it led32
  1. Machine learning models for prediction of lymph node metastasis in patients with gastric cancer: a Chinese single-centre study with external validation in an Asian American population.2025BMJ openFree full text
  2. Development and current status of anti-reflux esophagogastrostomy after proximal gastrectomy: a literature review.2025Langenbeck's archives of surgeryFree full text
  3. Development and Characterization of the [177Lu]Lu-Labeled Anti-CDH17 Nanobody Derivative for Radioimmunotherapy in the Gastric Cancer Xenograft Model.2025Molecular pharmaceuticsFree full text
  4. Postoperative hypotension in gastric cancer patients: causes and clinical approaches.2025Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  5. Metabolic regulation of amino acids provides an important basis for individualized nutritional therapy for patients with gastric cancer during the perioperative period.2025World journal of surgical oncologyFree full text
  6. Incidence and risk of remnant gastric cancer after gastrectomy for gastric cancer: a population-based study from the SEER database.2024BMC gastroenterologyFree full text
  7. A case-series study of hepatic left lateral segment inversion for surgical field exposure in laparoscopic gastrectomy.2024BMC surgeryFree full text
  8. Tumor-derived Prevotella intermedia aggravates gastric cancer by enhancing Perilipin 3 expression.2024Cancer scienceFree full text
  9. DDX24 promotes tumor progression by mediating hexokinase-1 induced glycolysis in gastric cancer.2024Cellular signalling
  10. MiR-30a-5p isoform -1|1 promotes the progression of gastric cancer by inhibiting TMEM66 and reducing intratumoral cytotoxic T cells.2024Experimental cell research
  11. Investigating MATN3 and ASPN as novel drivers of gastric cancer progression via EMT pathways.2024Human molecular genetics
  12. CircFNTA promotes tumorigenesis and progression of gastric cancer via miR-604/miR-647/SCN8A axis.2024Journal of biochemical and molecular toxicology
  13. The relationship between splenic dose and radiation-induced lymphopenia.2024Journal of radiation researchFree full text
  14. RAI2 acts as a tumor suppressor with functional significance in gastric cancer.2023AgingFree full text
  15. High expression of serine protease 2 (PRSS2) associated with invasion, metastasis, and proliferation in gastric cancer.2023AgingFree full text
  16. Decreased KLF3 Expression via miR-660-5p Targeting Suppresses Gastric Cancer Cell Progression.2023Annals of clinical and laboratory science
  17. METTL3 regulates N6-methyladenosine modification of ANGPTL3 mRNA and potentiates malignant progression of stomach adenocarcinoma.2023BMC gastroenterologyFree full text
  18. Peripheral CD4+CD25hiCD127low regulatory T cells are increased in patients with gastrointestinal cancer.2023BMC gastroenterologyFree full text
  19. Laparoscopic proximal gastrectomy with right-sided overlap and single-flap valvuloplasty (ROSF): a case-series study.2023BMC surgeryFree full text
  20. Development and validation of a multiphase CT radiomics nomogram for the preoperative prediction of lymphovascular invasion in patients with gastric cancer.2023Clinical radiology
  21. Exosomal circ_0091741 promotes gastric cancer cell autophagy and chemoresistance via the miR-330-3p/TRIM14/Dvl2/Wnt/β-catenin axis.2023Human cell
  22. MST4 as a novel therapeutic target for autophagy and radiosensitivity in gastric cancer.2023IUBMB life
  23. Targeting ROR1 inhibits glucocorticoid-induced gastric cancer growth.2023Steroids
  24. Inhibition of Musashi-1 enhances chemotherapeutic sensitivity in gastric cancer patient-derived xenografts.2022Experimental biology and medicine (Maywood, N.J.)Free full text
  25. PRaG Therapy of Refractory Metastatic Gastric Cancer: A Case Report.2022Frontiers in immunologyFree full text
  26. Current status of internal hernia after gastrectomy for gastric cancer.2022Langenbeck's archives of surgery
  27. Clinicopathological Analysis and Prognostic Assessment of TCN1 in Patients with Gastric Cancer.2022Surgical innovation
  28. Current status of laparoscopic proximal gastrectomy in proximal gastric cancer: Technical details and oncologic outcomes.2021Asian journal of surgery
  29. TYMSOS drives the proliferation, migration, and invasion of gastric cancer cells by regulating ZNF703 via sponging miR-4739.2021Cell biology international
  30. Mast1 mediates radiation-induced gastric injury via the P38 MAPK pathway.2021Experimental cell research
  31. Esophagus two-step-cut overlap method in esophagojejunostomy after laparoscopic gastrectomy.2021Langenbeck's archives of surgery
  32. UFBP1, a key component in ufmylation, enhances drug sensitivity by promoting proteasomal degradation of oxidative stress-response transcription factor Nrf2.2021Oncogene
Chinese-language papers (not in the count)4
  1. [Application status of vagus nerve preservation and double-flap technique in laparoscopic proximal gastrectomy].2025Zhonghua wai ke za zhi [Chinese journal of surgery]
  2. [Artificial intelligence for lymph node metastasis prediction in gastric cancer: research progress].2025Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  3. [A preliminary exploration of reduced port laparoscopic proximal gastrectomy with right-sided overlap and single-flap valvuloplasty (ROSF)].2024Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  4. [Immune-Related Pancreatitis Caused by Immune Checkpoint Inhibitor Nivolumab:Report of One Case].2023Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
All its trials on ClinicalTrials.gov, any status10
  1. Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric CancerRecruitingNCT07552402Study siteN/AStart 2026-06
  2. Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction CancerRecruitingNCT06731478Study sitePhase 3Start 2025-02
  3. Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) OverexpressionCompletedNCT05052801Study sitePhase 3Start 2022-03
  4. HFNO Combined With NPA Reduces Hypoxia During Sedated Gastrointestinal Endoscopy In Obese PatientsStatus unknownNCT05526339Study siteN/AStart 2022-09
  5. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.TerminatedNCT05111626Study sitePhase 3Start 2022-03
  6. Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901CompletedNCT04805307Study sitePhase 1Start 2020-12
  7. Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell InjectionActive, not recruitingNCT04581473Study sitePhase 1/Phase 2Start 2020-10
  8. HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric CancerStatus unknownNCT04486651Study sitePhase 3Start 2020-09
  9. A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction CancerCompletedNCT03694522Study sitePhase 2Start 2018-09
  10. Enhanced Recovery After Surgery Program for Gastric Cancer: a Multi-center StudyStatus unknownNCT03121729Study siteN/AStart 2017-06

Run the PubMed searchClinicalTrials.gov

Cancer

Lung cancer

肺癌

Led 64 of the 23,356 English-language PubMed papers on lung cancer with an author in mainland China, 2021–2025: 0.3%.

Papers led
64
2021–2025
Trials led
4
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 151520212022: 9920222023: 131320232024: 9920242025: 18182025

3 hospitals in Suzhou for lung cancer251 hospitals in China for lung cancer

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    The Impact of Thoracic Paravertebral Nerve Block At Different Positions on Pain Relief in Patients Undergoing Single-Port Thoracoscopic Partial Lung Resection
    Phase
    N/A
    Started
    2025-01
    Posted
    Registry
    NCT06789276

    Age 18 years to 70 years (registered criteria)

    Led by Second Affiliated Hospital of Soochow UniversitySuzhou

  2. Recruiting
    Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
    Phase
    Phase 1/Phase 2
    Started
    2023-04
    Posted
    Registry
    NCT05786924

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Jinan, Shanghai, Suzhou

  3. Not yet recruiting
    YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
    Phase
    Phase 3
    Started
    2023-05
    Posted
    Registry
    NCT05767892

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Hohhot, Jinan, Kunming, Luoyang, Nanchang, Nanjing, Qingdao, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Wuhan, Xi'an, Xiamen, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersRadiation oncologyRadiology / nuclear medicineMedical oncologyPathology / laboratory medicine
Papers it led64
  1. A combined model integrating radiomics and deep learning based on multiparametric magnetic resonance imaging for classification of brain metastases.2025Acta radiologica (Stockholm, Sweden : 1987)
  2. A Neovascularization and EGFR Dual-Targeting Gold Nanotheranostic System for Non-Small Cell Lung Cancer Treatment.2025Advanced healthcare materials
  3. Distinct CTC Specific RNA Profile Enables NSCLC Early Detection and Dynamic Monitoring of Advanced NSCLC.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  4. Lymphocyte-to-C-reactive protein ratio predicts prognosis in unresectable locally advanced non-small cell lung cancer patients.2025Annals of medicineFree full text
  5. Feasibility and mechanism of 68Ga-FAPI PET/CT in monitoring chemoresistance of non-small cell lung cancer.2025Annals of nuclear medicine
  6. MicroRNA-486: a dual-function biomarker for diagnosis and tumor immune microenvironment characterization in non-small cell lung cancer.2025BMC medical genomicsFree full text
  7. The mechanism of E3 ubiquitin ligase HERC1 regulating ferroptosis in lung adenocarcinoma cells.2025Cancer genetics
  8. IGF2BP3 Triggers STAT3 Pathway by Stabilizing SRC RNA in an m6A-Dependent Manner to Promote Lymphatic Metastasis in LUAD.2025Cancer scienceFree full text
  9. NADH:ubiquinone oxidoreductase core subunit S8 expression and functional significance in non-small cell lung cancer.2025Cell death & diseaseFree full text
  10. Mitochondrial carrier homolog 2 is important for mitochondrial functionality and non-small cell lung cancer cell growth.2025Cell death & diseaseFree full text
  11. Expression patterns of MCM8 in lung adenocarcinoma and its correlation with key biological processes.2025European journal of medical researchFree full text
  12. Risk factors and intraoperative identification of non-lepidic predominant lung adenocarcinoma presenting as subsolid nodule: A multicenter study.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  13. Suppressor of Tumorigenicity 14 inhibits non-small cell lung cancer cell proliferation by suppressing Transketolase O-GlcNAcylation.2025Experimental cell research
  14. Radiomics based on dual-layer spectral detector CT for predicting EGFR mutation status in non-small cell lung cancer.2025Journal of applied clinical medical physicsFree full text
  15. Prognostic implications, genomic and immune characteristics of lung adenocarcinoma with lepidic growth pattern.2025Journal of clinical pathology
  16. Targeting the lung tumour stroma: harnessing nanoparticles for effective therapeutic interventions.2025Journal of drug targeting
  17. TRANS: a prediction model for EGFR mutation status in NSCLC based on radiomics and clinical features.2025Respiratory researchFree full text
  18. Which descriptor should spread through air spaces (STAS) be incorporated into? T descriptor versus residual tumor classification.2025The journal of pathology. Clinical researchFree full text
  19. Comparison of lung lesion assessment using free-breathing dynamic contrast-enhanced 1.5-T MRI with a golden-angle radial stack-of-stars VIBE sequence and CT.2024Acta radiologica (Stockholm, Sweden : 1987)
  20. Keratin 6A (KRT6A) promotes radioresistance, invasion, and metastasis in lung cancer via p53 signaling pathway.2024AgingFree full text
  21. Elevated origin recognition complex subunit 6 expression promotes non-small cell lung cancer cell growth.2024Cell death & diseaseFree full text
  22. Ectopic Expression of TIGIT in Lung Adenocarcinoma and Its Clinical Significance.2024Critical reviews in eukaryotic gene expression
  23. 2.5D deep learning based on multi-parameter MRI to differentiate primary lung cancer pathological subtypes in patients with brain metastases.2024European journal of radiology
  24. CXCL5 impedes CD8+ T cell immunity by upregulating PD-L1 expression in lung cancer via PXN/AKT signaling phosphorylation and neutrophil chemotaxis.2024Journal of experimental & clinical cancer research : CRFree full text
  25. Lipid alterations play a role in the integration of PD-1/PD-L1 inhibitors and anlotinib for the treatment of advanced non-small-cell lung cancer.2024Lipids in health and diseaseFree full text
  26. Tislelizumab combined with GT chemotherapy for intimal sarcoma of inferior vena cava: A case report.2024MedicineFree full text
  27. GIMAP7 inhibits epithelial-mesenchymal transition and glycolysis in lung adenocarcinoma cells via regulating the Smo/AMPK signaling pathway.2024Thoracic cancerFree full text
  28. Identification of epithelial-mesenchymal transition-related biomarkers in lung adenocarcinoma using bioinformatics and lab experiments.2023AgingFree full text
  29. POLRMT over-expression is linked to WNT/beta-catenin signaling, immune infiltration, and unfavorable outcomes in lung adenocarcinoma patients.2023Cancer medicineFree full text
  30. Clinical implications and molecular features of tertiary lymphoid structures in stage I lung adenocarcinoma.2023Cancer medicineFree full text
  31. FDW028, a novel FUT8 inhibitor, impels lysosomal proteolysis of B7-H3 via chaperone-mediated autophagy pathway and exhibits potent efficacy against metastatic colorectal cancer.2023Cell death & diseaseFree full text
  32. Clinical profiles and intraoperative identification of complex glands in stage I lung adenocarcinoma.2023European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  33. CYFIP2 serves as a prognostic biomarker and correlates with tumor immune microenvironment in human cancers.2023European journal of medical researchFree full text
  34. EUS-guided ethanol ablation for management of lung carcinoma (with video).2023Gastrointestinal endoscopy
  35. Identification of WD-Repeat Protein 72 as a Novel Prognostic Biomarker in Non-Small-Cell Lung Cancer.2023Mediators of inflammationFree full text
  36. Sarcopenia as a Determinant of the Efficacy of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: A Meta-Analysis.2023Nutrition and cancer
  37. Plasma metabolomics for the assessment of the progression of non-small cell lung cancer.2023The International journal of biological markers
  38. Characteristics and risk factors for advanced lung cancer with pulmonary embolism: A cross-sectional, case-control study.2023The clinical respiratory journalFree full text
  39. Characterization of TCF-1 and its relationship between CD8+ TIL densities and immune checkpoints and their joint influences on prognoses of lung adenocarcinoma patients.2023Thoracic cancerFree full text
  40. Oncogenic zinc finger protein ZNF687 accelerates lung adenocarcinoma cell proliferation and tumor progression by activating the PI3K/AKT signaling pathway.2023Thoracic cancerFree full text
  41. Impact of clinical and molecular features on efficacy and outcome of patients with non-small cell lung cancer receiving second-line osimertinib.2022BMC cancerFree full text
  42. Efficacy and safety of anlotinib with and without EGFR-TKIs or immunotherapy in the treatment of elder patients with non-small-cell lung cancer: a retrospective study.2022BMC pulmonary medicineFree full text
  43. Insulin-Like Growth Factor 2 mRNA-Binding Protein 3 and Its Related Molecules as Potential Biomarkers in Small-Cell Lung Cancer.2022BioMed research internationalFree full text
  44. Roles of DNA polymerase ζ in the radiotherapy sensitivity and oxidative stress of lung cancer cells.2022Cancer chemotherapy and pharmacology
  45. Comment on "clinicopathological features, survival outcomes, and appropriate surgical approaches for stage I acinar and papillary predominant lung adenocarcinoma".2022Cancer medicineFree full text
  46. Targeting sphingosine kinase 1/2 by a novel dual inhibitor SKI-349 suppresses non-small cell lung cancer cell growth.2022Cell death & diseaseFree full text
  47. Image classification of immune checkpoint inhibitor-related pneumonia in lung cancer patients.2022Clinical imaging
  48. Identification of the mitochondrial protein ADCK2 as a therapeutic oncotarget of NSCLC.2022International journal of biological sciencesFree full text
  49. Log odds of positive lymph nodes is a robust predictor of survival and benefits from postoperative radiotherapy in stage IIIA-N2 resected non-small cell lung cancer.2022Thoracic cancerFree full text
  50. Potentiated lung adenocarcinoma (LUAD) cell growth, migration and invasion by lncRNA DARS-AS1 via miR-188-5p/ KLF12 axis.2021AgingFree full text
  51. LncRNA LOC100129620 promotes osteosarcoma progression through regulating CDK6 expression, tumor angiogenesis, and macrophage polarization.2021AgingFree full text
  52. Overexpression of hsa_circ_0002874 promotes resistance of non-small cell lung cancer to paclitaxel by modulating miR-1273f/MDM2/p53 pathway.2021AgingFree full text
  53. Characterization of Extracapsular Lymph Node Involvement and Its Clinicopathological Characteristics in Stage II-IIIA Lung Adenocarcinoma.2021Annals of surgical oncology
  54. ASO Author Reflections: Old Song, New Sung-Extracapsular Extension in Lung Cancer in the Era of Eighth-Edition N Classification.2021Annals of surgical oncology
  55. Stromal-derived miR-486-5p promotes metastasis of non-small-cell lung cancer cells by targeting the CADM1/tight junctions axis in vascular endothelial cells.2021Cell biology international
  56. The requirement of mitochondrial RNA polymerase for non-small cell lung cancer cell growth.2021Cell death & diseaseFree full text
  57. M2 macrophage-derived exosomal long non-coding RNA AGAP2-AS1 enhances radiotherapy immunity in lung cancer by reducing microRNA-296 and elevating NOTCH2.2021Cell death & diseaseFree full text
  58. Clinical implications of the pattern of recurrence of pN2 non-small-cell lung cancer.2021European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  59. MiR-221-3p-mediated downregulation of MDM2 reverses the paclitaxel resistance of non-small cell lung cancer in vitro and in vivo.2021European journal of pharmacology
  60. FUCA2 Is a Prognostic Biomarker and Correlated With an Immunosuppressive Microenvironment in Pan-Cancer.2021Frontiers in immunologyFree full text
  61. Differentiation of pulmonary sclerosing pneumocytoma from solid malignant pulmonary nodules by radiomic analysis on multiphasic CT.2021Journal of applied clinical medical physicsFree full text
  62. Letter to the Editor: Clinical Implications of Postoperative Radiotherapy on Patient Survival in Stage IIIA Resected Lung Cancer: More Variables Should Be Considered.2021Journal of the National Comprehensive Cancer Network : JNCCN
  63. Characterization of CD66b and its relationship between immune checkpoints and their synergistic impact in the prognosis of surgically resected lung adenocarcinoma.2021Lung cancer (Amsterdam, Netherlands)
  64. A novel GHR-ALK fusion gene in a patient with metastatic lung adenocarcinoma and its response to crizotinib: a case report.2021The Journal of international medical researchFree full text
Chinese-language papers (not in the count)5
  1. [Radiotherapy Combined with Immunotherapy and Chemotherapy Improves Prognosis and Demonstrates Synergistic Effects in Extensive-stage Small Cell Lung Cancer].2024Zhongguo fei ai za zhi = Chinese journal of lung cancerFree full text
  2. [Efficacy Analysis of High-flow Nasal Oxygen Therapy in Patients 
Accepting Single-port Video-assisted Thoracoscopic Lobectomy].2022Zhongguo fei ai za zhi = Chinese journal of lung cancerRCTFree full text
  3. [Progress in Single-cell RNA Sequencing of Lung Adenocarcinoma].2021Zhongguo fei ai za zhi = Chinese journal of lung cancerFree full text
  4. [Clinicopathological and genetic features of metastatic lung cancer to the adrenal glands: report of four cases].2021Zhonghua bing li xue za zhi = Chinese journal of pathology
  5. [Differential diagnosis of pure ground glass nodules in lung with spectral CT imaging].2021Zhonghua yi xue za zhi
All its trials on ClinicalTrials.gov, any status14
  1. The Impact of Thoracic Paravertebral Nerve Block At Different Positions on Pain Relief in Patients Undergoing Single-Port Thoracoscopic Partial Lung ResectionNot yet recruitingNCT06789276Lead sponsorN/AStart 2025-01
  2. A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor in Combination With PRaG for Advanced Refractory Non-small Cell Lung CancerStatus unknownNCT06047860Lead sponsorPhase 2Start 2023-06
  3. Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0)Status unknownNCT05603013Lead sponsorPhase 2Start 2022-10
  4. Preoperative and Postoperative ctDNA Comparison in Early Stage Lung CancerStatus unknownNCT03805256Lead sponsorStart 2018-05
  5. YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion MutationsNot yet recruitingNCT05767892Study sitePhase 3Start 2023-05
  6. Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive MalignanciesRecruitingNCT05786924Study sitePhase 1/Phase 2Start 2023-04
  7. ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 InhibitorsActive, not recruitingNCT05671510Study sitePhase 3Start 2023-06
  8. Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)CompletedNCT05298423Study sitePhase 3Start 2022-05
  9. Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung CancerTerminatedNCT04921358Study sitePhase 3Start 2021-07
  10. A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung CancerTerminatedNCT04746924Study sitePhase 3Start 2021-05
  11. A Study to Compare the Similarity in Efficacy and Safety Between TRS003 and China-approved Bevacizumab® in NSCLCStatus unknownNCT04416035Study sitePhase 3Start 2020-08
  12. Neoadjuvant PD-1 Antibody Plus Chemotherapy in Resectable Stage IIIA-N2 Non-Small-Cell Lung CancerTerminatedNCT04422392Study sitePhase 2Start 2020-07
  13. Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC)CompletedNCT03358875Study sitePhase 3Start 2017-11
  14. Recombinant Endostatin Combined With Vinorelbine and Cisplatin in Patients With Advanced Non-small Cell Lung CancerCompletedNCT03117335Study sitePhase 3Start 2011-11

Run the PubMed searchClinicalTrials.gov

Cancer

Pancreatic cancer

胰腺癌

Led 11 of the 5,743 English-language PubMed papers on pancreatic cancer with an author in mainland China, 2021–2025: 0.2%.

Papers led
11
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 3320212022: 0020222023: 2220232024: 3320242025: 332025

2 hospitals in Suzhou for pancreatic cancer192 hospitals in China for pancreatic cancer

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Safety and Efficacy of NRT6008 in Patients With Unresectable Locally Advanced Pancreatic Cancer (LAPC) and Advanced Pancreatic Cancer With Lymph Node Metastases
    Phase
    Phase 1
    Started
    2024-01
    Posted
    Registry
    NCT06278454

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesChongqing, Shanghai, Suzhou, Tianjin, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)Gastroenterology / hepatology
Papers it led11
  1. GALNT4-induced O-GalNAc glycosylation of MUC1 accelerates the invasive phenotype of PDAC.2025Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  2. A Phase I/II Study Protocol of a Novel Neoadjuvant 'PRaG' Regimen (Radiotherapy, GM-CSF, and Cadonilimab) with AG Chemotherapy to Improve Resectability in Locally Advanced Pancreatic Ductal Adenocarcinoma: The NeoPRAG Study.2025Technology in cancer research & treatmentFree full text
  3. The impact of the muscle mass-to-fat ratio on the prognosis of patients undergoing pancreaticoduodenectomy for pancreatic cancer.2025The Kaohsiung journal of medical sciencesFree full text
  4. Macroscopic on-site magnifier-based evaluation to estimate visible tissue core cut-off lengths using EUS-FNA with 22-gauge needles.2024Chinese medical journalFree full text
  5. YAP-LAMB3 axis dictates cellular resistance of pancreatic ductal adenocarcinoma cells to gemcitabine.2024Molecular carcinogenesis
  6. PRaG 3.0 therapy for human epidermal growth factor receptor 2-positive metastatic pancreatic ductal adenocarcinoma: A case report.2024World journal of gastroenterologyFree full text
  7. Identification of matrix-remodeling associated 5 as a possible molecular oncotarget of pancreatic cancer.2023Cell death & diseaseFree full text
  8. EUS-guided ethanol ablation for management of lung carcinoma (with video).2023Gastrointestinal endoscopy
  9. Individualized prognostic signature for pancreatic carcinoma validated by integrating immune-related gene pairs (IRGPs).2021BioengineeredFree full text
  10. Elevated expression of nuclear receptor-binding SET domain 3 promotes pancreatic cancer cell growth.2021Cell death & diseaseFree full text
  11. Hepatobiliary and Pancreatic: Endoscopic resection of biliary ductal tumour.2021Journal of gastroenterology and hepatology
All its trials on ClinicalTrials.gov, any status3
  1. Safety and Efficacy of NRT6008 in Patients With Unresectable Locally Advanced Pancreatic Cancer (LAPC) and Advanced Pancreatic Cancer With Lymph Node MetastasesRecruitingNCT06278454Study sitePhase 1Start 2024-01
  2. Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901CompletedNCT04805307Study sitePhase 1Start 2020-12
  3. Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell InjectionActive, not recruitingNCT04581473Study sitePhase 1/Phase 2Start 2020-10

Run the PubMed searchClinicalTrials.gov

Cancer

Breast cancer

乳腺癌

Led 27 of the 16,974 English-language PubMed papers on breast cancer with an author in mainland China, 2021–2025: 0.2%.

Papers led
27
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
3
led by another institution
Papers led per year
2021: 4420212022: 6620222023: 1120232024: 7720242025: 772025

2 hospitals in Suzhou for breast cancer219 hospitals in China for breast cancer

Open trials with this hospital 4

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Clinical Study of Darcilil Combined With AI Combined With Pyrrotinib in the Treatment of TPBC
    Phase
    N/A
    Started
    2024-02
    Posted
    Registry
    NCT06235931

    Age 65 years to Not stated; women only (registered criteria)

    Led by Second Affiliated Hospital of Soochow UniversitySuzhou

  2. Recruiting
    JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
    Phase
    Phase 3
    Started
    2023-12
    Posted
    Registry
    NCT06079983

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 60 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Hengyang, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Meizhou, Nanchang, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xiangyang, Xining, Xinxiang, Xuzhou, Zhanjiang, Zhengzhou, Zunyi

  3. Recruiting
    A Study of YL202 in Selected Patients With Advanced Solid Tumors
    Phase
    Phase 2
    Started
    2023-12
    Posted
    Registry
    NCT06107686

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guilin, Hangzhou, Harbin, Hefei, Jinan, Meizhou, Nanchang, Nanning, Qingdao, Shanghai, Shantou, Shenyang, Suzhou, Taiyuan, Taizhou, Urumqi, Weifang, Wuhan, Xi'an, Xiangyang, Xuzhou, Zhengzhou

  4. Enrolling by invitation
    A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC
    Phase
    Phase 2
    Started
    2025-08
    Posted
    Registry
    NCT07376629

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 22 listed hospitals as study sitesAnyang, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanjing, Shanghai, Shenyang, Suzhou, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Xuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)Medical oncologyPathology / laboratory medicineRadiation oncology

Over half of these papers are lab or animal studies.

Papers it led27
  1. Radiological-pathological correlation in encapsulated papillary carcinoma of the breast.2026Annals of diagnostic pathology
  2. Circ_0057582 inhibits breast cancer progression via hnRNPF/YAP/SOX9 axis and M2 polarization in TAMs by autophagic degradation of ISG15.2026Biochemical pharmacology
  3. Collagen Hydrogel Loaded With 9-cisRA-Lip Is an Option for Treatment of Secondary Lymphedema after Surgery.2025Cancer biotherapy & radiopharmaceuticals
  4. Hyaluronic acid and polyvinyl alcohol-based radioresponsive hydrogel for combined radioimmunotherapy of breast cancer bone metastasis.2025Carbohydrate polymers
  5. Study on Heparanase Promoting Breast Cancer Cell Proliferation and Inhibiting NK Cell Cytolytic Activity Via the PD-1/PD-L1 Pathway.2025Clinical breast cancer
  6. Development and validation of a novel sodium-overload related genes signature for prognostic prediction in breast cancer: integrating bioinformatics and experimental approaches.2025Frontiers in immunologyFree full text
  7. Igniting tumour microenvironment in triple-negative breast cancer using a mannose/hyaluronic acid dual-coated Ganoderma polysaccharide-superparamagnetic iron oxide nanocomplex for combinational therapies.2025Journal of drug targeting
  8. Innovative applications of visualized thermosensitive color-changing personalized boluses in post-mastectomy radiotherapy: a dosimetric analysis.2025Radiation oncology (London, England)RCTFree full text
  9. Leucine rich repeat containing 15 promotes triple-negative breast cancer proliferation and invasion via the ITGB1/FAK/PI3K signalling pathway.2025Scientific reportsFree full text
  10. A novel SERS-lateral flow assay (LFA) tray for monitoring of miR-155-5p during pyroptosis in breast cancer cells.2024Analytical methods : advancing methods and applications
  11. The novel circRNA circ_0045881 inhibits cell proliferation and invasion by targeting mir-214-3p in triple-negative breast cancer.2024BMC cancerFree full text
  12. A comprehensive evaluation of circ_0065214/ miR-188-3p/GPNMB axis in breast cancer.2024Cellular signalling
  13. Exosomal miR-122-3p represses the growth and metastasis of MCF-7/ADR cells by targeting GRK4-mediated activation of the Wnt/β-catenin pathway.2024Cellular signalling
  14. SNHG14 promotes triple-negative breast cancer cell proliferation, invasion, and chemoresistance by regulating the ERK/MAPK signaling pathway.2024IUBMB life
  15. Metabolism-regulating non-coding RNAs in breast cancer: roles, mechanisms and clinical applications.2024Journal of biomedical scienceFree full text
  16. LINC01929 Is a Prognostic Biomarker for Multiple Tumours and Promotes Cell Proliferation in Breast Cancer Through the TNF/STAT3 Axis.2024Journal of cellular and molecular medicineFree full text
  17. Letter to the editor regarding "Association between gout and subsequent breast cancer: a retrospective cohort study including 67,598 primary care patients in Germany".2023Breast cancer research and treatment
  18. Tumor-promoting mechanisms of macrophage-derived extracellular vesicles-enclosed microRNA-660 in breast cancer progression.2022Breast cancer research and treatment
  19. HOXD9 transcriptionally induced UXT facilitate breast cancer progression via epigenetic modification of RND3.2022Cellular signalling
  20. KLF14 alleviated breast cancer invasion and M2 macrophages polarization through modulating SOCS3/RhoA/Rock/STAT3 signaling.2022Cellular signalling
  21. LINC00680 modulates docetaxel resistance in breast cancer via the miR-320b/CDKL5 axis.2022International journal of immunopathology and pharmacologyFree full text
  22. A novel prognostic model associated with the overall survival in patients with breast cancer based on lipid metabolism-related long noncoding RNAs.2022Journal of clinical laboratory analysisFree full text
  23. CTCF-Induced lncRNA C5orf66-AS1 Facilitates the Progression of Triple-Negative Breast Cancer via Sponging miR-149-5p to Up-Regulate CTCF and CTNNB1 to Activate Wnt/β-Catenin Pathway.2022Molecular and cellular biologyFree full text
  24. Transcription factor KLF2 enhances the sensitivity of breast cancer cells to cisplatin by suppressing kinase WEE1.2021Cancer biology & therapyFree full text
  25. Lobetyolin inhibits the proliferation of breast cancer cells via ASCT2 down-regulation-induced apoptosis.2021Human & experimental toxicology
  26. The role of ferroptosis-related genes for overall survival prediction in breast cancer.2021Journal of clinical laboratory analysisFree full text
  27. B7-H3 on breast cancer cell MCF7 inhibits IFN-γ release from tumour-infiltrating T cells.2021Pathology, research and practice
All its trials on ClinicalTrials.gov, any status9
  1. A Clinical Study of Darcilil Combined With AI Combined With Pyrrotinib in the Treatment of TPBCRecruitingNCT06235931Lead sponsorN/AStart 2024-02
  2. Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0)Status unknownNCT05603013Lead sponsorPhase 2Start 2022-10
  3. A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBCEnrolling by invitationNCT07376629Study sitePhase 2Start 2025-08
  4. A Study of YL202 in Selected Patients With Advanced Solid TumorsRecruitingNCT06107686Study sitePhase 2Start 2023-12
  5. JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer SubjectsRecruitingNCT06079983Study sitePhase 3Start 2023-12
  6. PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBCActive, not recruitingNCT06419621Study sitePhase 3Start 2024-06
  7. A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast CancerStatus unknownNCT05433480Study sitePhase 3Start 2022-05
  8. Comparative Study on Two Post-operative Adjuvant Chemotherapy Regimens for Treating Triple-negative Breast CancerStatus unknownNCT01642771Study sitePhase 3Start 2012-06
  9. Neoadjuvant Treatment of Docetaxel, Anthracycline and Cyclophosphamide (TAC) Versus Docetaxel and Cyclophosphamide (TC) in Triple-Negative or Her2 Positive Breast CancerTerminatedNCT00912444Study sitePhase 3Start 2009-07

Run the PubMed searchClinicalTrials.gov

Cancer

Glioma

胶质瘤

Led 44 of the 7,081 English-language PubMed papers on glioma with an author in mainland China, 2021–2025: 0.6%.

Papers led
44
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 101020212022: 6620222023: 121220232024: 4420242025: 11112025

4 hospitals in Suzhou for glioma187 hospitals in China for glioma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Study of GC101 TIL in Brain Glioma (Soochow2)
    Phase
    Early phase 1
    Started
    2021-05
    Posted
    Registry
    NCT04943913

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteSuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersNeurosurgeryRadiation oncologyNeurologyRadiology / nuclear medicine

Over half of these papers are lab or animal studies.

Papers it led44
  1. Selenoprotein P drives glioma malignancy via LRP8-dependent activation of Wnt/β-catenin signaling.2026Cellular signalling
  2. Procollagen C-protease enhancer protein promotes glioma growth by activating ERK signaling.2025Asia-Pacific journal of clinical oncologyFree full text
  3. MDA-9/Syntenin promotes glioma cell proliferation and invasion via exosome-mediated activation of the PI3K-AKT signaling pathway.2025Biochemical and biophysical research communications
  4. FDX1 facilitates elesclomol-induced cuproptosis and promotes glioblastoma development via transcription factor NFKB1.2025Biochemical pharmacology
  5. KIF4A Promotes Glioblastoma Malignant Progression and Transmission of Temozolomide Resistance in the Tumor Microenvironment via the HIF1A/VEGFA Axis.2025CNS neuroscience & therapeuticsFree full text
  6. Amlodipine synergizes with temozolomide against glioma stem cells by modulating MGMT expression through downregulation of the AKT/GSK3β/β-catenin axis.2025Cellular signalling
  7. SRBD1 Regulates the Cell Cycle, Apoptosis, and M2 Macrophage Polarization via the RPL11-MDM2-p53 Pathway in Glioma.2025Environmental toxicology
  8. The miR-192/EGR1-HOXB9 loop inhibits immune evasion in glioma by arresting their NSC phenotypes.2025International immunopharmacology
  9. The miR-192-EGR1/HOXB9 Loop Regulates Glioma Cell Stemness and Malignant Phenotypes by Promoting Their Mesenchymal Transition.2025Journal of cellular and molecular medicineFree full text
  10. KIF4A Inhibits Ferroptosis in Glioblastoma via the CHMP4B/GPX4 Axis and Promotes Temozolomide Resistance.2025Molecular carcinogenesis
  11. KRT80, Regulated by RNF8-Mediated Ubiquitination, Contributes to Glucose Metabolic Reprogramming and Progression of Glioblastoma.2025Neurochemical research
  12. Immuno-oncological interactions between meningeal lymphatics and glioblastoma: from mechanisms to therapies.2025TheranosticsFree full text
  13. Transformed astrocytes confer temozolomide resistance on glioblastoma via delivering ALKBH7 to enhance APNG expression after educating by glioblastoma stem cells-derived exosomes.2024CNS neuroscience & therapeuticsFree full text
  14. Efficacy and safety of anlotinib combined with the STUPP regimen in patients with newly diagnosed glioblastoma: a multicenter, single-arm, phase II trial.2024Cancer biology & medicineFree full text
  15. Glioma stem cell-derived exosomes induce the transformation of astrocytes via the miR-3065-5p/DLG2 signaling axis.2024Glia
  16. SENP1-Mediated deSUMOylation Regulates the Tumor Remodeling of Glioma Stem Cells Under Hypoxic Stress.2024Technology in cancer research & treatmentFree full text
  17. Interferon-γ inducible protein 30 promotes the epithelial-mesenchymal transition-like phenotype and chemoresistance by activating EGFR/AKT/GSK3β/β-catenin pathway in glioma.2023CNS neuroscience & therapeuticsFree full text
  18. Exosomal miR-6733-5p mediates cross-talk between glioblastoma stem cells and macrophages and promotes glioblastoma multiform progression synergistically.2023CNS neuroscience & therapeuticsFree full text
  19. Upregulation of the ZNF148/PTX3 axis promotes malignant transformation of dendritic cells in glioma stem-like cells microenvironment.2023CNS neuroscience & therapeuticsFree full text
  20. RNA-binding protein DHX9 promotes glioma growth and tumor-associated macrophages infiltration via TCF12.2023CNS neuroscience & therapeuticsFree full text
  21. Exosome-Mediated Transfer of circ-GLIS3 Enhances Temozolomide Resistance in Glioma Cells Through the miR-548m/MED31 Axis.2023Cancer biotherapy & radiopharmaceuticals
  22. LILRB2-containing small extracellular vesicles from glioblastoma promote tumor progression by promoting the formation and expansion of myeloid-derived suppressor cells.2023Cancer immunology, immunotherapy : CIIFree full text
  23. LncRNA SPRY4-IT1 facilitates cell proliferation and angiogenesis of glioma via the miR-101-3p/EZH2/VEGFA signaling axis.2023Cancer medicineFree full text
  24. The FDX1 methylation regulatory mechanism in the malignant phenotype of glioma.2023Genomics
  25. PA2G4P4 Promotes Glioma Cell Migration and Tumorigenesis through the PTEN/AKT/mTOR Signaling Pathway.2023Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer
  26. HDAC1 mediates epithelial-mesenchymal transition and promotes cancer cell invasion in glioblastoma.2023Pathology, research and practice
  27. YME1L overexpression exerts pro-tumorigenic activity in glioma by promoting Gαi1 expression and Akt activation.2023Protein & cellFree full text
  28. Rare adult pilocytic astrocytoma of the septum pellucidum with novel RIN2::BRAF fusion.2023Virchows Archiv : an international journal of pathology
  29. Molecular characteristics of single patient-derived glioma stem-like cells from primary and recurrent glioblastoma.2022Anti-cancer drugsFree full text
  30. MEOX2-mediated regulation of Cathepsin S promotes cell proliferation and motility in glioma.2022Cell death & diseaseFree full text
  31. RIT1 Promotes Glioma Proliferation and Invasion via the AKT/ERK/NF-ĸB Signaling Pathway.2022Journal of molecular neuroscience : MN
  32. TM4SF1 promotes glioma malignancy through multiple mechanisms.2022Neoplasma
  33. GBP3 promotes glioblastoma resistance to temozolomide by enhancing DNA damage repair.2022Oncogene
  34. Gliosarcoma with osteosarcomatous component: A case report and short review illustration.2022Pathology, research and practice
  35. Nicardipine sensitizes temozolomide by inhibiting autophagy and promoting cell apoptosis in glioma stem cells.2021AgingFree full text
  36. A retrospective analysis of the risk factors affecting recurrence time in patients with recurrent glioblastoma.2021Annals of palliative medicine
  37. Integrative analysis of TP73 profile prognostic significance in WHO grade II/III glioma.2021Cancer medicineFree full text
  38. Circ_0001367 inhibits glioma proliferation, migration and invasion by sponging miR-431 and thus regulating NRXN3.2021Cell death & diseaseFree full text
  39. GBP5 drives malignancy of glioblastoma via the Src/ERK1/2/MMP3 pathway.2021Cell death & diseaseFree full text
  40. Do the combination of multiparametric MRI-based radiomics and selected blood inflammatory markers predict the grade and proliferation in glioma patients?2021Diagnostic and interventional radiology (Ankara, Turkey)Free full text
  41. FHL1 promotes glioblastoma aggressiveness through regulating EGFR expression.2021FEBS letters
  42. Doxorubicin Delivered via ApoE-Directed Reduction-Sensitive Polymersomes Potently Inhibit Orthotopic Human Glioblastoma Xenografts in Nude Mice.2021International journal of nanomedicineFree full text
  43. Self‑renewal signaling pathways and differentiation therapies of glioblastoma stem cells (Review).2021International journal of oncology
  44. Bioinformatics analysis reveals a stem cell-expressed circ-Serpine2-mediated miRNA-mRNA regulatory subnetwork in the malignant progression of glioma.2021Journal of translational medicineFree full text
Chinese-language papers (not in the count)1
  1. [Characteristics and regulatory mechanisms of lipid metabolism remodeling after malignant transformation of glioma-associated macrophages].2022Zhonghua yi xue za zhi
All its trials on ClinicalTrials.gov, any status2
  1. Safety and Efficacy of Targeted IL-13 Rα2 or B7-H3 UCAR-T for Advanced GliomaStatus unknownNCT05752877Lead sponsorN/AStart 2021-05
  2. Study of GC101 TIL in Brain Glioma (Soochow2)RecruitingNCT04943913Study siteEarly phase 1Start 2021-05

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 13 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.6%.

Papers led
13
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 5520212022: 3320222023: 1120232024: 3320242025: 112025

14 hospitals in Suzhou for osteosarcoma570 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurosurgeryMedical oncology

Over half of these papers are lab or animal studies.

Papers it led13
  1. STUB1-mediated ubiquitination of SLC25A10 regulates mitochondrial function and drives osteosarcoma progression: A novel therapeutic target.2025Cellular signalling
  2. KAT7 serves as an oncogenic gene and regulates CCL3 expression via STAT1 signaling in osteosarcoma.2024Biochemical and biophysical research communications
  3. Relationship between surgical compliance and survival outcome in patients with Ewing sarcoma.2024Indian journal of cancer
  4. Mitochondria targeted biomimetic platform for chemo/photodynamic combination therapy against osteosarcoma.2024International journal of pharmaceutics
  5. A Feedback Loop of LINC00665 and the Wnt Signaling Pathway Expedites Osteosarcoma Cell Proliferation, Invasion, and Epithelial-Mesenchymal Transition.2023Orthopaedic surgeryFree full text
  6. ADCK1 is a potential therapeutic target of osteosarcoma.2022Cell death & diseaseFree full text
  7. Identification of Gαi3 as a promising target for osteosarcoma treatment.2022International journal of biological sciencesFree full text
  8. Gliosarcoma with osteosarcomatous component: A case report and short review illustration.2022Pathology, research and practice
  9. LncRNA LOC100129620 promotes osteosarcoma progression through regulating CDK6 expression, tumor angiogenesis, and macrophage polarization.2021AgingFree full text
  10. COL3A1 and Its Related Molecules as Potential Biomarkers in the Development of Human Ewing's Sarcoma.2021BioMed research internationalFree full text
  11. ARHGEF3 Associated with Invasion, Metastasis, and Proliferation in Human Osteosarcoma.2021BioMed research internationalFree full text
  12. miRNA-296-5p functions as a potential tumor suppressor in human osteosarcoma by targeting SND1.2021Chinese medical journalFree full text
  13. Propofol suppresses osteosarcoma cell function by regulating FOXO1/TUSC7.2021The Journal of pharmacy and pharmacology
Earlier papers (2016–2020)9
  1. MicroRNA-187 suppresses the proliferation migration and invasion of human osteosarcoma cells by targeting MAPK7.2020Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  2. High Expression of N-Acetylgalactosaminyl-transferase 1 (GALNT1) Associated with Invasion, Metastasis, and Proliferation in Osteosarcoma.2020Medical science monitor : international medical journal of experimental and clinical research
  3. Proliferation inhibition and apoptosis promotion by dual silencing of VEGF and Survivin in human osteosarcoma.2019Acta biochimica et biophysica Sinica
  4. EP1 receptor is involved in prostaglandin E2-induced osteosarcoma growth.2019Bosnian journal of basic medical sciences
  5. TCF3-activated LINC00152 exerts oncogenic role in osteosarcoma through regulating miR-1182/CDK14 axis.2019Pathology, research and practice
  6. Long noncoding RNA SNHG6 promotes osteosarcoma cell proliferation through regulating p21 and KLF2.2018Archives of biochemistry and biophysics
  7. MiR-299-5p targets cell cycle to promote cell proliferation and progression of osteosarcoma.2018European review for medical and pharmacological sciences
  8. The anti-tumor effect of pachymic acid on osteosarcoma cells by inducing PTEN and Caspase 3/7-dependent apoptosis.2018Journal of natural medicines
  9. miR-29 Family Inhibits Resistance to Methotrexate and Promotes Cell Apoptosis by Targeting COL3A1 and MCL1 in Osteosarcoma.2018Medical science monitor : international medical journal of experimental and clinical research

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 1 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.2%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

7 hospitals in Suzhou for gastrointestinal stromal tumour240 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led 2 of the 163 English-language PubMed papers on Ewing sarcoma with an author in mainland China, 2021–2025: 1.2%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 002025

3 hospitals in Suzhou for Ewing sarcoma134 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncology

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 2 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.1%.

Papers led
2
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
3
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 002025

2 hospitals in Suzhou for multiple myeloma175 hospitals in China for multiple myeloma

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
    Phase
    Phase 1
    Started
    2026-05
    Posted
    Registry
    NCT07477587

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Weifang, Wenzhou, Wuhan, Wuxi, Xiamen, Xuzhou, Zhengzhou

  2. Recruiting
    A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors
    Phase
    Phase 1
    Started
    2025-12
    Posted
    Registry
    NCT07179679

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesChengde, Chongqing, Guangzhou, Nanchang, Nanchong, Nanjing, Shanghai, Suzhou, Xi'an

  3. Recruiting
    UTAA17 Injection in the Treatment of Relapsed/Refractory Multiple Myeloma
    Phase
    N/A
    Started
    2024-04
    Posted
    Registry
    NCT06279026

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteSuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesDrug combinations
Papers it led2
  1. Multiple myeloma with high expression of SLC7A11 is sensitive to erastin-induced ferroptosis.2024Apoptosis : an international journal on programmed cell death
  2. Anti-BCMA-engineered exosomes for bortezomib-targeted delivery in multiple myeloma.2024Blood advancesFree full text
Chinese-language papers (not in the count)5
  1. [The Role and Possible Mechanism of T Cell Costimulatory Molecule CD28 Activation in Pathogenesis of Multiple Myeloma].2025Zhongguo shi yan xue ye xue za zhi
  2. [The Impact of SRSF1 -Mediated Alternative Splicing of RBBP6 on the Proliferation of Multiple Myeloma Cells].2024Zhongguo shi yan xue ye xue za zhi
  3. [Bone Marrow Adipocytes Promote the Survival of Multiple Myeloma Cells and Up-Regulate Their Chemoresistance].2023Zhongguo shi yan xue ye xue za zhi
  4. [Clinical Significance of CD28 Expression in Newly Diagnosed Multiple Myeloma].2022Zhongguo shi yan xue ye xue za zhi
  5. [Effect of the Connexin 43 Coupling to the Biobehavior of Multiple Myeloma Cells].2021Zhongguo shi yan xue ye xue za zhi
All its trials on ClinicalTrials.gov, any status7
  1. Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed/Refractory Multiple MyelomaStatus unknownNCT05857982Lead sponsorPhase 1/Phase 2Start 2023-05
  2. Combination of G-CSF, Bortezomib, Cyclophosphamide and Dexamethasone in Patients With Multiple MyelomaStatus unknownNCT02027220Lead sponsorPhase 2Start 2013-12
  3. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple MyelomaRecruitingNCT07477587Study sitePhase 1Start 2026-05
  4. A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell TumorsRecruitingNCT07179679Study sitePhase 1Start 2025-12
  5. UTAA17 Injection in the Treatment of Relapsed/Refractory Multiple MyelomaRecruitingNCT06279026Study siteN/AStart 2024-04
  6. A Clinical Trial of TQB2934 for Injection in Multiple Myeloma SubjectsStatus unknownNCT05646758Study sitePhase 1Start 2023-03
  7. Clinical Trial of BCMA CAR T Cell Infusion in Patients With BCMA-positive r/r Multiple MyelomaStatus unknownNCT04186052Study siteEarly phase 1Start 2019-03

Run the PubMed searchClinicalTrials.gov

Blood disorders

Lymphoma

淋巴瘤

Led 10 of the 3,830 English-language PubMed papers on lymphoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
10
2021–2025
Trials led
4
any status, ClinicalTrials.gov
Open trials led
3
recruiting or about to
Open trials as a site
3
led by another institution
Papers led per year
2021: 1120212022: 3320222023: 0020232024: 1120242025: 552025

2 hospitals in Suzhou for lymphoma199 hospitals in China for lymphoma

Open trials with this hospital 6

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    An Open-label, Single-arm, Multicenter Phase II Clinical Study of Azacitidine, Chidamide Combined With PD-1 Monoclonal Antibody in the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma.
    Phase
    Early phase 1
    Started
    2026-06
    Posted
    Registry
    NCT07598578

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Soochow UniversitySuzhou

  2. Recruiting
    Selinexor, High-dose Methotrexate, and Rituximab Combined With Radiotherapy for Newly Diagnosed, Transplant-ineligible Patients With Central Nervous System Lymphoma: An Open-label, Single-arm, Multicenter Phase II Study
    Phase
    Phase 2
    Started
    2025-06
    Posted
    Registry
    NCT07002099

    Age 18 years to Not stated (registered criteria)

    Led by Second Affiliated Hospital of Soochow UniversitySuzhou

  3. Not yet recruiting
    Plasma cfDNA Testing Guiding the Treatment Decisions of DLBCL
    Phase
    N/A
    Started
    2024-02
    Posted
    Registry
    NCT06289959

    Age 18 years to Not stated (registered criteria)

    Led by Second Affiliated Hospital of Soochow UniversitySuzhou

  4. Recruiting
    A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2025-07
    Posted
    Registry
    NCT07124936

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan, Kunming, Nanchang, Nanning, Shenyang, Suzhou, Taiyuan, Wuhan, Xi'an, Zhengzhou

  5. Recruiting
    Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Phase
    Phase 3
    Started
    2024-05
    Posted
    Registry
    NCT06521255

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Nanchang, Shanghai, Suzhou, Tianjin, Urumqi, Wenzhou, Wuhan, Zhengzhou

  6. Recruiting
    A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor
    Phase
    Phase 1
    Started
    2024-08
    Posted
    Registry
    NCT06615193

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesHangzhou, Jinan, Nanchang, Suzhou, Tianjin, Xuzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersPathology / laboratory medicine

Over half of these papers are lab or animal studies.

Papers it led10
  1. Circulating tumor DNA from blood and cerebrospinal fluid in DLBCL: simultaneous evaluation of mutations, IG rearrangement, and IG clonality.2025British journal of cancerFree full text
  2. Glofitamab treatment of Richter transformation with isolated central nervous system involvement: a case report.2025Frontiers in immunologyFree full text
  3. An anti-CD19-exosome delivery system navigates the blood-brain barrier for targeting of central nervous system lymphoma.2025Journal of nanobiotechnologyFree full text
  4. Combined Inhibition of XPO1 and DNA Methylation Exerts Synergistic Effects in DLBCL.2025Molecular carcinogenesis
  5. A novel cancer-associated fibroblast-related gene signature for predicting diffuse large B cell lymphoma prognosis using weighted gene co-expression network analysis and machine learning.2025The Journal of international medical researchFree full text
  6. A promising natural product in diffuse large B-cell lymphoma therapy by targeting PIM1.2024Annals of hematology
  7. Diffuse large B-cell lymphoma-derived exosomes push macrophage polarization toward M2 phenotype via GP130/STAT3 signaling pathway.2022Chemico-biological interactions
  8. CCL8 as a promising prognostic factor in diffuse large B-cell lymphoma via M2 macrophage interactions: A bioinformatic analysis of the tumor microenvironment.2022Frontiers in immunologyFree full text
  9. EZH2 inhibitor DZNep blocks cell proliferation of GCB-DLBCL cells by upregulating p16.2022Leukemia & lymphoma
  10. piRNA-30473 contributes to tumorigenesis and poor prognosis by regulating m6A RNA methylation in DLBCL.2021Blood
All its trials on ClinicalTrials.gov, any status16
  1. An Open-label, Single-arm, Multicenter Phase II Clinical Study of Azacitidine, Chidamide Combined With PD-1 Monoclonal Antibody in the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma.RecruitingNCT07598578Lead sponsorEarly phase 1Start 2026-06
  2. Selinexor, High-dose Methotrexate, and Rituximab Combined With Radiotherapy for Newly Diagnosed, Transplant-ineligible Patients With Central Nervous System Lymphoma: An Open-label, Single-arm, Multicenter Phase II StudyRecruitingNCT07002099Lead sponsorPhase 2Start 2025-06
  3. Plasma cfDNA Testing Guiding the Treatment Decisions of DLBCLNot yet recruitingNCT06289959Lead sponsorN/AStart 2024-02
  4. Chidamide in Patients With Recurrent and Refractory Diffuse Large bStatus unknownNCT05690191Lead sponsorStart 2021-06
  5. A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell LymphomaRecruitingNCT07124936Study sitePhase 1/Phase 2Start 2025-07
  6. A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid TumorRecruitingNCT06615193Study sitePhase 1Start 2024-08
  7. Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell LymphomaRecruitingNCT06521255Study sitePhase 3Start 2024-05
  8. Obinutuzumab in Chinese Real-world Patients With iNHLStatus unknownNCT05968001Study siteStart 2023-07
  9. A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) .Status unknownNCT05959694Study sitePhase 1/Phase 2Start 2023-10
  10. TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL)TerminatedNCT06106841Study sitePhase 1/Phase 2Start 2023-10
  11. Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular LymphomaCompletedNCT04849351Study sitePhase 2Start 2021-04
  12. A Phase 1 Study of TRS005 in Patients With R/R CD20-positive B-NHL.Active, not recruitingNCT05395533Study sitePhase 1Start 2020-09
  13. The Clinical Application of Chimeric Antigen Receptor T Cells in the Treatment of CD19 Positive Recurrent Refractory B Cell-derived Hematological MalignanciesStatus unknownNCT04184414Study siteEarly phase 1Start 2018-01
  14. A Study to Evaluate the Efficacy and Safety of Bendamustine Hydrochloride InjectionCompletedNCT04569838Study sitePhase 2Start 2012-05
  15. A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)TerminatedNCT01287741Study sitePhase 3Start 2011-07
  16. A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell LymphomaTerminatedNCT00486759Study sitePhase 3Start 2007-07

Run the PubMed searchClinicalTrials.gov

Other diseases

Fabry disease

法布雷病

Led no English-language PubMed papers on Fabry disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

3 hospitals in Suzhou for Fabry disease80 hospitals in China for Fabry disease

No open trial on Fabry disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Duchenne muscular dystrophy

杜氏肌营养不良

Led no English-language PubMed papers on Duchenne muscular dystrophy in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

3 hospitals in Suzhou for Duchenne muscular dystrophy111 hospitals in China for Duchenne muscular dystrophy

No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led 1 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

3 hospitals in Suzhou for Behçet disease139 hospitals in China for Behçet disease

No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)
Papers it led1
  1. Identification of biomarkers for abdominal aortic aneurysm in Behçet's disease via mendelian randomization and integrated bioinformatics analyses.2024Journal of cellular and molecular medicineFree full text
Earlier papers (2016–2020)1
  1. [Progress in interferon: A treatment of Behcet syndrome].2020Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 1 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

6 hospitals in Suzhou for IgA nephropathy300 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led no English-language PubMed papers on primary biliary cholangitis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

4 hospitals in Suzhou for primary biliary cholangitis153 hospitals in China for primary biliary cholangitis

No open trial on primary biliary cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. A Study of the Pharmacokinetics and Safety of CS0159 in Subjects With Hepatic InjuryCompletedNCT06888115Study sitePhase 1Start 2025-03

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

苏州大学附属第二医院

Second Affiliated Hospital of Soochow University

苏州

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
Second Affiliated Hospital of SooChow University; General Hospital of Nuclear Industry; Sino-France Friendship Hospital

Suggest a correctionDownload the data